|21.05|| +0.25 / +1.20%|
Impax Laboratories, Inc. operates as a technology based specialty pharmaceutical company, which engages in the development, manufacture, and marketing of controlled-release and niche generics. It operates through the Impax Generics and Impax Specialty Pharma segments. The Impax Generics segment concentrates on the development manufacture, sale and distribution of generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established nonproprietary drug names rather than by a brand name. The Impax Specialty Pharma segment engages in the development of proprietary brand pharmaceutical products. The company was founded on December 14, 1999 and is headquartered in Hayward, CA.
|Paul M. Bisaro||President, Chief Executive Officer & Director|
|Andrew Schaschl||Senior Vice President-Global Operations|
|Bryan M. Reasons||Chief Financial Officer & Senior VP-Finance|
|Jeffrey D. Nornhold||Senior Vice President-Technical Operations|
|Vishal K. Gupta||CSO, Senior Vice President-Research & Development|